|
|
||||||||
1 The Jackson Laboratory, 600 Main Street, Bar Harbor, Maine 04609
2 GlaxoWellcome, Laboratoire Glaxo Wellcome, Centre de Recherches, 91951 Les Ulis Cedex, France
3 Department of Medicine, Northwest Lipid Research Laboratories, University of Washington, Seattle, Washington 98103
4 GlaxoWellcome, Molecular Pathology, Medicines Research Centre, Stevenage, United Kingdom
| ABSTRACT |
|---|
|
|
|---|
high-density lipoprotein; cholesterol; genetics; Srb1
| INTRODUCTION |
|---|
|
|
|---|
Although human studies and transgenic and knockout mice have provided valuable insights into the relationships between HDL-C concentrations and the known lipoproteins and apolipoproteins (7), our understanding of the factors that regulate HDL concentrations and the mechanisms responsible for the protective effect of HDL remain poorly understood. Furthermore, although these methodologies allow for the study of known genes, they do not provide opportunities for the discovery of new genes involved in HDL metabolism. The rapidly developing technique of quantitative trait locus (QTL) analysis can be used to discover new genes (11, 23, 27). QTL mapping has been important in the identification of several loci involved in the development of atherosclerotic lesions (35, 38, 39, 53) and in the regulation of plasma lipid concentrations (16, 25, 26, 40, 50, 55).
In this paper, we report the use of QTL mapping to identify several loci that regulate concentrations of plasma HDL and non-HDL lipoproteins [very-low-density lipoprotein (VLDL) and low-density lipoprotein (LDL)] in the SM/J (SM) and NZB/B1NJ (NZB) inbred strains of mice. Our data confirm QTL identified in previous, independent studies using the same (40) and different (16, 25, 26, 50) strains of mice and identify additional loci involved in controlling plasma HDL and non-HDL cholesterol concentrations. We also present the results of tests carried out to determine whether Srb1 is a viable candidate gene for one HDL-C QTL.
| METHODS |
|---|
|
|
|---|
Lipid measurements.
At 0 and 18 wk of diet consumption, mice were fasted for 4 h before blood was collected for lipid determinations. Blood was collected by retro-orbital bleeding into EDTA-coated tubes, and plasma was separated by centrifugation at 1,500 rpm for 5 min at 4°C. Plasma total cholesterol (TC) concentrations were measured by commercial colorimetric enzymatic assay as described previously (4). HDL cholesterol (HDL-C) was measured after selective precipitation of apo B-containing lipoproteins with polyethylene glycol (18). The results are means ± SE in millimoles per liter.
HDL size determinations.
HDL size was measured by nondenaturing polyacrylamide gel electrophoresis (PAGE) and fast performance liquid chromatography (FPLC). For the PAGE analysis, 20 µl of plasma and 10 µl of high-molecular-weight standards (Pharmacia Biotech, Piscataway, NJ) were electrophoresed on preformed 430% polyacrylamide gels (Alamo Gels, San Antonio, TX) in 0.09 M Tris, 0.08 M boric acid, 0.003 M EDTA, pH 8.35, at 200 V for 20 h at 4°C. Lipoproteins and molecular weight standards were visualized with Sudan Black B and Coomassie G250, respectively, and scanned with a laser densitometer (LKB Ultroscan XL) as described previously (8). For the FPLC analysis, two Superose columns, Superose 6 and Superose 12 (Pharmacia Biotech), were connected in series and equilibrated in 10 mM Tris, 1 mM EDTA, 150 mM NaCl, pH 7.4. Lipoprotein separation was performed on 250 µl of pooled plasma from 10 animals, at a flow rate of 0.3 ml/min in the previously described buffer. Fractions of 500 µl were collected, and 50 µl of each fraction was mixed with 200 µl of direct cholesterol determination reagent PAP250 (Biomerieux-France). After a 15-min incubation at 37°C, optical density was measured at 492 nm, and the cholesterol concentration in each fraction was calculated using a cholesterol standard curve ranging from 0 to 1.0 g/l. Cholesterol concentrations were plotted, and determination of the VLDL, LDL, and HDL cholesterol concentrations was realized after integration of the three corresponding peaks.
Immunoblot and RNA blot analysis of livers for Srb1.
To determine whether SR-B1 protein and mRNA concentrations differ between the parental strains, we performed Western blot and total liver mRNA Northern blot analyses. Mouse livers were frozen in liquid N2 immediately after harvesting and stored at - 80°C. Membrane fractions for immunoblotting were prepared from pulverized livers as previously described (24). For Northern blot analysis, 15-µg aliquots of total cellular mRNA were electrophoresed on a 1% (wt/vol) agarose, 0.59% (vol/vol) formaldehyde gel in the following buffer: 20 mM MOPS, 1 mM EDTA, 5 mM sodium acetate, pH 7.0. The fractionated mRNA was transferred in 10x SSC to Hybond N+ nylon membrane (Amersham, Arlington Heights, IL), ultraviolet (UV) cross-linked, and then probed for SR-B1 as previously described (24).
Isolation and sequencing of Srb1 cDNA.
Total RNA isolated from SM and NZB liver was reverse-transcribed using Messagemaker cDNA Synthesis System (GIBCO-BRL). A series of overlapping primers (Table 1), designed to span the Srb1 mouse sequence (1) (GenBank accession number U37799), was used for PCR amplification with the following conditions: 94°C for 45 s, 58°C for 45 s, and 72°C for 2 min. Most PCR products were sequenced directly, but the PCR product amplified by primers 1 forward and 147 reverse was cloned into the TA-Cloning vector system (Invitrogen). Cycle sequencing was performed using M13 forward (CAGGAAACAGCTATGAC) and reverse (CAGCACTGACCCTTTTG) universal primers and analyzed on an Applied Biosystems 373 machine.
|

to
of one spleen were digested overnight in 500 µl of 1x digestion buffer (50 mM Tris·HCl, pH 8.0, 100 mM EDTA pH 8.0, 100 mM NaCl, 1% SDS, 1 mg/ml proteinase K) in a 55°C water bath. Digests were mixed with 1 volume of 25:24:1 phenol:chloroform:isoamyl alcohol and centrifuged for 5 min at 14,000 rpm at room temperature. DNA was precipitated by adding 2 volumes of 100% ethanol to the isolated aqueous phase. Strands of DNA were wound around a glass capillary pipette and air-dried. The dried DNA pellets were resuspended in 1 ml TE (10 mM Tris·HCl, 1 mM EDTA, pH 7.58.0). Genotyping by PCR using mouse MIT MapPairs primers (Research Genetics, Huntsville, AL) was carried out under standard conditions at an annealing temperature of 55°C. To detect polymorphisms as small as 6 bp, PCR products were electrophoresed on 8% horizontal polyacrylamide gels in 1x Tris-borate-EDTA running buffer for 2 h at 180 V. Gels were stained with ethidium bromide and photographed over short-wave UV light.
QTL analysis.
From blood samples collected at 0 and 18 wk time points, both TC and HDL-C were measured. From these measurements, VLDL and LDL cholesterol values were calculated by subtracting HDL-C from TC. In the mouse, the major atherogenic lipoprotein is VLDL, but small quantities of LDL are also present (17); these lipoproteins are therefore referred to collectively as non-HDL-C. Additionally, we calculated an inducible HDL-C value (Ind HDL-C) and an inducible non-HDL-C value from the ratio of the lipid values at 18 wk to that at 0 wk. Therefore, six phenotypic traits were obtained: HDL-C 0 wk, HDL-C 18 wk, non-HDL-C 0 wk, non-HDL-C 18 wk, Ind HDL-C, and Ind non-HDL-C. For QTL analysis, 15 animals at the high and low extremes for each trait were selected to be genotyped. Since some mice were at the extremes for more than one trait, 53 of the 89 backcross mice were genotyped. The genome-wide scan was conducted using 78 simple sequence length polymorphism (SSLP) markers with 35 markers per chromosome (Table 2), except for additional markers typed on those chromosomes with a significant QTL. Because the percentage of polymorphic markers between NZB and SM is only
30% compared with 50% for most other strains, the number of useful markers for our cross was limited. More markers were added later on chromosomes 5 and 6 to refine QTL in those regions. The average distance between markers was 2025 centimorgans (cM), except on chromosomes 2, 10, and X where gaps of more than 30 cM exist due to a lack of polymorphic markers in these regions. Centimorgan positions listed throughout this paper are from the Mouse Genome Informatics database (http://www.informatics.jax.org).
|
In addition to QTL with main effects, we wished to identify pairs of QTL that might make significant contributions to the phenotypic variance through epistatic interactions. We carried out simultaneous genome scans for all pairs of loci using the method of Sen and Churchill (47). The search strategy employed has been described by Sugiyama et al. (49). Briefly, the genome scan searches through all pairs of loci fitting a full two-way ANOVA model with an interaction term. A LOD score contrasting the full model to a null model (with no genetic effects) is computed for each pair, and genome-wide significance is established by permutation testing. A secondary test for the significance of the interaction term is computed only for those pairs that pass the genome-wide screening. The interaction test is carried out using a stringent nominal significance level (0.005), and only those locus pairs passing both tests are deemed to be interacting. In this study, no significant interactions were identified; however, one significant QTL (on chromosome 19) was identified in the pairwise analysis that was not detectable in the main effects genome scans. To assess the combined effects of all QTL on a trait, we carried out a multiple QTL analysis for each trait including all suggestive and significant QTL. The percent of variance explained by each QTL is reported based on this model. The multiple regression was fit using all of the data in the pseudomarker software package to properly account for missing genotypes in the calculation of percent variance explained. A new function "panova" was created for this purpose, and it is available in pseudomarker release version 9.1 (http://www.jax.org/research/churchill). Comparisons of cholesterol and Srb1 mRNA and protein concentrations were performed using Statview II (Abacus Concepts, Berkeley, CA). Between-group comparisons were analyzed by one-way ANOVA, using Fishers least significant difference test to determine statistical significance. All values are expressed as means ± SE. The numbers of mice used for each experiment are specified in the individual Figs. 15 and Tables 16.
|
|
|
|
|
|
|
|
|
| RESULTS |
|---|
|
|
|---|
Strains NZB and SM also differ from one another in HDL particle size as determined by analysis of pooled samples (Fig. 1). The peak of the HDL particle size as determined by PAGE (Fig. 1A) lay further from the origin in NZB (9.86 nm) than in SM (9.32 nm) when mice were fed the chow diet; this difference became more pronounced after 6 wk on the atherogenic diet, as the HDL peak moved in NZB to 10.46 nm while it remained unchanged in SM (9.29 nm). Consistent with these results, the FPLC profiles (Fig. 1B) demonstrated that the shift toward larger particle size in NZB became more pronounced as the time on the atherogenic diet was extended. Thus both methods demonstrate that HDL particles are larger in NZB than SM mice, regardless of diet.
QTL analysis of factors affecting lipoprotein concentrations.
To investigate genetic factors regulating plasma lipoproteins, we carried out a backcross and collected 90 female backcross progeny. The distribution of HDL-C concentrations for the backcross progeny at both 0 and 18 wk were unimodal (Fig. 2, A and B), suggesting that multiple loci of small to moderate effect determine these phenotypes. The mean (±SE) HDL-C concentrations at 0 (2.56 ± 0.04 mmol/l) and 18 (4.0 ± 0.1 mmol/l) wk fell between those of the parental strains but more closely resembled those of the NZB parent than those of the SM parent. The distribution for inducible HDL-C in the backcross progeny was also unimodal (Fig. 2C), and the mean inducible HDL-C for the backcross progeny was 1.6 ± 0.04, similar to both parental strains.
The genotyping of mice and statistical analysis for QTL identified several loci associated with these traits. Figure 3 shows the genome-wide scans for HDL-C at 0 wk, HDL-C at 18 wk, induced HDL-C, non-HDL-C at 0 wk, non-HDL-C at 18 wk, and induced non-HDL-C. The significant (P < 0.05) and suggestive (P < 0.2) loci identified are shown in Table 4. For chow-fed mice, the NZB alleles near D5Mit370 and D18Mit34 are associated with high HDL-C concentration; heterozygosity at either locus is associated with a reduction in HDL-C. Both loci are highly significant (Table 4) and assigned as Hdlq1 and Hdlq3, respectively. The fitted model using these two QTL explains 24% of the total variance (Table 5). In mice fed the high-fat diet, the NZB alleles near D5Mit239 and D19Mit71 are associated with high HDL-C concentrations. The QTL on chromosome 19 did not achieve significance in the scan for single QTL but did achieve significance in the pairwise QTL genome scan (LOD = 6.4). Heterozygosity at either locus is associated with a reduction of HDL-C. The locus at D5Mit239 is highly significant (Table 4) and assigned Hdlq2. The fitted model with the QTL on chromosomes 5 and 19 explains 25% of the total variance for HDL-C in high-fat diet fed mice (Table 5).
For inducible HDL-C, expressed as log(HDL-18 wk/HDL-0 wk), the locus near D15Mit39 is associated with higher induction in heterozygotes (Table 4) and assigned Hdlq4. Near loci D6Mit44 and D18Mit24 are suggestive QTL. The model including all three loci explains 23% of the variance in this trait (Table 5). By itself, D15Mit39 explains 12% of the variance. The absence of significant effects associated with loci on chromosome 5 is somewhat surprising and may be the result of undetected interactions with other loci.
Analysis of the 0 wk non-HDL-C concentrations identified suggestive association on chromosome 11. For 18 wk non-HDL-C there is a peak on chromosome 11 that reaches the suggestive level. SM alleles on chromosome 11 are associated with increased levels of non-HDL-C.
We derived a value for inducible non-HDL-C from the ratio of the value at 18 wk on diet to that at 0 wk on diet. No suggestive associations were noted for inducible non-HDL-C. However, very little non-HDL-C is present in the chow-fed mouse and these low concentrations are too close to the background of the assay, so measurement noise obscures the phenotype for inducible non-HDL-C.
The chromosome 5 LOD curves for HDL-C on standard chow and high-fat diets have distinct peaks at 65 and 45 cM, respectively (Fig. 4). Posterior densities for the QTL locations on chromosome 5 are well separated, and the 95% confidence intervals have limited overlap. These observations raise the possibility that there may be two QTL on this chromosome, each having an effect on only one of the two HDL-C measurements. To test the hypothesis of two vs. one QTL, we computed the LOD scores for a multitrait analysis (5, 19) under the assumption of one QTL and two QTL. The difference in LOD scores is converted to a chi-square statistic with two degrees of freedom (
22 = 5.88, P = 0.053). The marginal significance of this test provides modest support for the two-QTL hypothesis. We favor the conclusion that there are two distinct QTL rather than a single QTL with pleiotropic effects. However, further investigation of this region is needed to reach a definitive conclusion.
Srb1 as a possible candidate gene for Hdlq1.
Previous genetic analyses have also identified QTL for HDL-C on chromosome 5 (25, 26, 40) and mapped the scavenger receptor, class B, type I, Srb1, to distal chromosome 5 near the QTL at D5Mit370 (54). Since the SR-B1 protein has been shown to be an HDL receptor (1), we considered Srb1 as a possible candidate gene for this QTL. This is a particularly attractive hypothesis because the HDL-C phenotype in strain NZB resembles the phenotype of the Srb1 knockout mice (45) in the elevated concentrations and increased size of HDL. To determine whether Srb1 is a viable candidate gene, we performed Western immunoblot analyses on liver membranes and Northern blot analyses on total liver mRNA from the parental strains fed either the standard chow or the atherogenic diet for 18 wk (Fig. 5; Table 6). Levels of Srb1 mRNA were not significantly different in NZB than in SM when mice were consuming the chow diet. Since the QTL that mapped close to Srb1 was observed in chow-fed mice, the failure to observe a significant difference in mRNA in these animals does not support the hypothesis that Srb1 is the candidate gene. Levels of Srb1 mRNA were upregulated significantly (P < 0.002) in SM but not in NZB after 18 wk on the atherogenic diet. This resulted in a significantly higher level of Srb1 mRNA in SM compared with NZB mice after 18 wk (P < 0.001). Concentrations of SR-B1 protein in the liver were similar in NZB and SM when mice were consuming the standard chow diet, a result that also fails to support the role of Srb1 as a candidate gene. After 18 wk on the atherogenic diet, SR-BI protein concentrations were significantly (P < 0.01) decreased in both strains but to a greater degree in SM than in NZB, resulting in a significantly (P < 0.03) lower concentration of liver SR-BI protein in SM than in NZB. These data indicate that diet regulates the concentrations of liver Srb1 mRNA only in SM and regulates the concentrations of liver SR-BI protein in both SM and NZB.
Although strains SM and NZB do not differ in Srb1 mRNA or protein concentrations in chow-fed mice, Srb1 could differ in function between the two strains. Since such a functional difference would require a change in amino acid sequence of the protein, we isolated mRNA from both NZB and SM livers, synthesized and amplified the cDNA in two overlapping fragments, and determined their sequences. The NZB and SM sequences were aligned with the complete cDNA sequence obtained from the 3T3-L1 adipocyte cell line. A single transition from a T to C was found in strain NZB at bp 1535. Although this change does not change the amino acid sequence, it does remove an AluI site.
| DISCUSSION |
|---|
|
|
|---|
Some of the loci identified in this study confirm loci identified by QTL analysis in previous work, whereas others are new loci. Previous QTL analyses using an NZB x SM F2 cross (40), a B6 x C3H F2 cross (25), and a Cast x B6 F2 intercross (26) identified QTL on chromosome 5 for HDL-C concentrations. Purcell-Huynh and coworkers (40) identified a coincident QTL for HDL-C concentrations in mice fed the chow diet and in those fed the atherogenic diet within an
20-cM long region on the distal end of chromosome 5. Machleder and coworkers (25) identified an overlapping QTL for HDL-C concentrations in mice fed an atherogenic diet that spanned a portion of the central region of chromosome 5. None of these analyses detected two distinct loci, one for chow-fed and one for atherogenic diet-fed mice, as we did in the present study. This may be the result of our use of a different method of QTL analysis and our use of a larger number of markers in the analysis. All of the previous studies used methods that are based on single QTL models whereas, we utilized both multitrait and multiple QTL models in our analysis. Our analysis suggested that two distinct QTL might exist. Although not unequivocal, this kind of information can be of value in follow up studies that attempt to confirm the QTL or identify the gene(s) responsible. Interestingly, a QTL for HDL-C has been mapped on human chromosome 4 (q13) (6), which is homologous to the region where we mapped Hdlq2.
The QTL for HDL-C at 0 wk on chromosome 18 (near D18Mit34) might be the same QTL found previously in a cross between C3H/HeJ and C57BL/6J (D18Mit124D18Mit142 at cM 2232) (25), and may be within the confidence interval of a chromosome 18 QTL found previously in a cross between SM and NZB (D18Mit7 at cM 50) (40). However, we included marker D18Mit9 at cM 42, which falls between D18Mit24 and D18Mit7, and did not detect significance there. We also found a new QTL not previously reported at D19Mit71 for HDL-C at 18 wk. Our QTL for non-HDL-C near D11Mit44 was previously identified as having an effect on cholesterol metabolism (25), although for different traits, plasma HDL-C, and mRNA levels of cholesterol-7
hydroxylase. The QTL we present on chromosome 6 for inducible HDL-C (D6Mit44) is also novel.
Several genes that encode proteins known to regulate HDL-C concentrations map to locations different from the QTL identified in this report; these include: Lcat on chromosome 8; hepatic lipase (Lipc) on chromosome 9; Apoa1 on chromosome 9; Apoa2 on chromosome 1; or Pltp on chromosome 2. Therefore, none of these genes can account for the observed differences in HDL-C concentrations between these two strains. In addition, the gene for cholesteryl ester transfer protein (Cetp) cannot be considered as a candidate gene for these QTL, as it is present in humans but not in mice.
The QTL for inducible HDL-C on chromosomes 6 and 15 do have interesting candidate genes in the regions. On chromosome 6 is the gene for the peroxisome-proliferator-activated receptor-
(Pparg), a transcription factor that is induced in macrophages by oxidized LDL (42). The consequences of induction are, in part, anti-inflammatory. On chromosome 15 is the gene for the
-subunit of the peroxisome-proliferator-activated receptor (Ppara), which stimulates the ß-oxidative degradation of fatty acids. Ppara is expressed in aortic smooth muscle cells; it has recently been shown that activators of PPARA inhibit the inflammatory response of smooth muscle cells (48). Since oxidized HDL is cleared from plasma faster than native HDL, any transcription factor that could reduce the oxidative and inflammatory response in artery walls could lead to increases in plasma HDL-C concentrations. Further experiments are needed to clarify whether Ppara and Pparg are promising candidates for the QTL on chromosomes 6 and 15.
However, we did identify one gene for which the mapping and functional evidence was sufficiently strong to merit testing as a candidate gene for our QTL. The murine Srb1 gene encodes the scavenger receptor, class B, type I (SR-BI), maps to the distal end of chromosome 5 (54), and has been identified as the first known cell-surface HDL-C receptor (1). Murine Srb1 is expressed most abundantly in liver and steroidogenic tissues (1, 24, 28). Hepatic overexpression of Srb1 reduces plasma HDL-C and increases cholesterol concentrations in bile (21), indicating that SR-BI is a physiologically significant HDL-C receptor. This key role for SR-BI in HDL-C metabolism was confirmed when investigators created a targeted null mutation in the gene for murine SR-BI. Srb1-null mice exhibited concentrations of HDL-C that were dramatically increased in the plasma but decreased in the adrenal gland and other steroidogenic tissues (45). Mice with the null mutation exhibited increased concentrations of large HDL-C particles. These changes in HDL-C concentration and particle size are similar to the HDL we observed in strain NZB and suggested to us that Srb1 is a strong candidate gene for this locus.
To test Srb1 as a candidate gene, we carried out experiments to determine whether Srb1 expression or its coding sequence differs between strains SM and NZB. We tested the expression of Srb1 protein and mRNA by performing Western analyses on liver membranes and Northern blot analyses on total liver mRNA, respectively. We anticipated that if Srb1 were the gene encoding the QTL for HDL, then strain NZB would exhibit lower concentrations of Srb1 mRNA and protein than SM on a standard chow diet. This would explain the higher basal concentrations of plasma HDL-C in NZB compared with SM, as Srb1 expression is inversely correlated with plasma concentrations of HDL-C. We also expected that when challenged with an atherogenic diet, both strains would exhibit decreased concentrations of Srb1 mRNA and protein, thereby explaining the inducibility of HDL-C in both strains; induction of Srb1 expression by the atherogenic diet would reduce plasma concentrations of HDL-C. We expected the decrease in Srb1 expression in response to the atherogenic diet to be more pronounced in strain NZB than in strain SM. Contrary to our expectations, there was not a significant difference between the basal levels of Srb1 mRNA in the liver between the SM and NZB strains when mice were fed a chow diet (Fig. 5; Table 6). Consistent with our observations of mRNA levels, there also was no significant difference between the basal concentrations of SR-BI protein in the liver between the SM and NZB strains when mice were fed the chow diet (Table 6). However, the effect of the atherogenic diet on Srb1 mRNA expression did not mirror its effect on Srb1 protein expression in either strain. When challenged with the atherogenic diet, liver concentrations of SR-BI protein decreased significantly in both strains. This lack of coordinate regulation of Srb1 mRNA and protein concentrations in mice fed an atherogenic diet has been observed previously (H. Hobbs, personal communication).
Since Srb1 expression did not differ between strains NZB and SM when mice were fed the chow diet, the HDL-C phenotype could be explained by a difference in Srb1 protein activity. Such a functional difference in the protein would be accompanied by a difference in the coding region of Srb1. However, sequencing the cDNA for Srb1 shows that the sequence is identical in strains NZB and SM with the exception of a single nucleotide polymorphism that does not result in an amino acid change. The expression and sequencing data does not provide persuasive evidence that Srb1 is a candidate gene for our HDL-C locus.
Similar analyses have been used to test Srb1 as a candidate gene for a QTL for HDL-C in a cross between CAST/Ei and C57BL/6J; these authors also were not able to find any evidence to support the candidacy of Srb1 (26). However, the possibility remains that some posttranslational difference in SR-BI occurs between strains NZB and SM. We have not attempted to test that possibility. Recent research has identified biochemical pathways involving SR-BI that could account for such a difference: SR-BI protein and mRNA are under hormonal regulation in mouse steroidogenic tissue (43, 44, 52) and levels of Srb1 mRNA are altered by mutations in apoA-I and LCAT (29, 52).
These QTL for plasma HDL-C and VLDL-C concentrations identify chromosomal regions containing genes that participate in lipoprotein metabolism. Identifying the genes responsible for these QTL offers the possibility of identifying novel genes affecting lipoprotein metabolism.
| ACKNOWLEDGMENTS |
|---|
This work was supported by GlaxoWellcome and by National Institutes of Health Grants HL-32087, HL-30086, and CA-34196.
| FOOTNOTES |
|---|
Address for reprint requests and other correspondence: B. Paigen, The Jackson Laboratory, 600 Main St., Bar Harbor, ME 04609 (E-mail: bjp{at}jax.org).
10.1152/ physiolgenomics.00107.2001.
| REFERENCES |
|---|
|
|
|---|
This article has been cited by other articles:
![]() |
J. E. Wergedal, C. L. Ackert-Bicknell, W. G. Beamer, S. Mohan, D. J. Baylink, and A. K. Srivastava Mapping genetic loci that regulate lipid levels in a NZB/B1NJxRF/J intercross and a combined intercross involving NZB/B1NJ, RF/J, MRL/MpJ, and SJL/J mouse strains J. Lipid Res., August 1, 2007; 48(8): 1724 - 1734. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. K. Srivastava, S. Mohan, G. L. Masinde, H. Yu, and D. J. Baylink Identification of quantitative trait loci that regulate obesity and serum lipid levels in MRL/MpJ x SJL/J inbred mice J. Lipid Res., January 1, 2006; 47(1): 123 - 133. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Asahina, M. Sato, and K. Imaizumi Genetic analysis of diet-induced hypercholesterolemia in exogenously hypercholesterolemic rats J. Lipid Res., October 1, 2005; 46(10): 2289 - 2294. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Korstanje, R. Li, T. Howard, P. Kelmenson, J. Marshall, B. Paigen, and G. Churchill Influence of sex and diet on quantitative trait loci for HDL cholesterol levels in an SM/J by NZB/BlNJ intercross population J. Lipid Res., May 1, 2004; 45(5): 881 - 888. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Lyons, R. Korstanje, R. Li, K. A. Walsh, G. A. Churchill, M. C. Carey, and B. Paigen Genetic contributors to lipoprotein cholesterol levels in an intercross of 129S1/SvImJ and RIIIS/J inbred mice Physiol Genomics, April 13, 2004; 17(2): 114 - 121. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. L. Welch, S. Bretschger, P.-Z. Wen, M. Mehrabian, N. Latib, J. Fruchart-Najib, J. C. Fruchart, C. Myrick, and A. J. Lusis Novel QTLs for HDL levels identified in mice by controlling for Apoa2 allelic effects: confirmation of a chromosome 6 locus in a congenic strain Physiol Genomics, March 12, 2004; 17(1): 48 - 59. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Lyons, H. Wittenburg, R. Li, K. A. Walsh, R. Korstanje, G. A. Churchill, M. C. Carey, and B. Paigen Quantitative trait loci that determine lipoprotein cholesterol levels in an intercross of 129S1/SvImJ and CAST/Ei inbred mice Physiol Genomics, March 12, 2004; 17(1): 60 - 68. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Korstanje, J. J. Albers, G. Wolfbauer, R. Li, A.-Y. Tu, G. A. Churchill, and B. J. Paigen Quantitative Trait Locus Mapping of Genes That Regulate Phospholipid Transfer Activity in SM/J and NZB/BlNJ Inbred Mice Arterioscler. Thromb. Vasc. Biol., January 1, 2004; 24(1): 155 - 160. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Wang, I. Le Roy, E. Nicodeme, R. Li, R. Wagner, C. Petros, G. A. Churchill, S. Harris, A. Darvasi, J. Kirilovsky, et al. Using Advanced Intercross Lines for High-Resolution Mapping of HDL Cholesterol Quantitative Trait Loci Genome Res., July 1, 2003; 13(7): 1654 - 1664. [Abstract] [Full Text] [PDF] |
||||
![]() |
X. Wang and B. Paigen Quantitative Trait Loci and Candidate Genes Regulating HDL Cholesterol: A Murine Chromosome Map Arterioscler. Thromb. Vasc. Biol., September 1, 2002; 22(9): 1390 - 1401. [Abstract] [Full Text] [PDF] |
||||
|
|